OBJECTIVE: to determine whether the favorable outcome associated with human papillomavirus (HPV) 16-positive oropharyngeal cancer is related to a patient's adaptive immunity. SETTING: academic medical center. PATIENTS: forty-seven of 66 previously untreated patients (6 of 20 patients with stage III and 41 of 46 with stage IV cancer) in a prospective clinical trial of chemoradiotherapy. INTERVENTION: all patients were treated with a single course of neoadjuvant chemotherapy followed by either surgery (for nonresponders) or chemoradiotherapy. MAIN OUTCOME MEASURES: pretreatment levels (percentages and absolute counts) of CD3, CD4, CD8, natural killer, and B cells and overall white blood cell counts were measured by flow cytometry. Correlations of subsets with HPV-16 status, tumor subsite, cancer stage, T class, N class, smoking status, performance status, sex, response to chemoradiotherapy, p53 mutation type, epidermal growth factor receptor expression, and disease-specific and overall survival were determined. RESULTS: after a median follow-up of 6.6 years, improved survival was associated with an elevated percentage of CD8 cells (P = .04), a low CD4:CD8 ratio (P = .01), low epidermal growth factor receptor expression (P = .002), and HPV status (P = .02). The percentage of CD8 cells was significantly higher (P = .04) and the CD4:CD8 ratio was significantly lower (P = .02) in HPV-16-positive patients. A higher percentage of CD8 cells was associated with response to induction chemotherapy (P = .02) and complete tumor response after chemoradiotherapy (P = .045). CONCLUSION: these findings confirm previous correlations of outcome with circulating CD8 cell levels and support the conjecture that improved adaptive immunity may play a role in the favorable prognosis of patients with HPV-16-positive cancers.
RCT Entities:
OBJECTIVE: to determine whether the favorable outcome associated with human papillomavirus (HPV) 16-positive oropharyngeal cancer is related to a patient's adaptive immunity. SETTING: academic medical center. PATIENTS: forty-seven of 66 previously untreated patients (6 of 20 patients with stage III and 41 of 46 with stage IV cancer) in a prospective clinical trial of chemoradiotherapy. INTERVENTION: all patients were treated with a single course of neoadjuvant chemotherapy followed by either surgery (for nonresponders) or chemoradiotherapy. MAIN OUTCOME MEASURES: pretreatment levels (percentages and absolute counts) of CD3, CD4, CD8, natural killer, and B cells and overall white blood cell counts were measured by flow cytometry. Correlations of subsets with HPV-16 status, tumor subsite, cancer stage, T class, N class, smoking status, performance status, sex, response to chemoradiotherapy, p53 mutation type, epidermal growth factor receptor expression, and disease-specific and overall survival were determined. RESULTS: after a median follow-up of 6.6 years, improved survival was associated with an elevated percentage of CD8 cells (P = .04), a low CD4:CD8 ratio (P = .01), low epidermal growth factor receptor expression (P = .002), and HPV status (P = .02). The percentage of CD8 cells was significantly higher (P = .04) and the CD4:CD8 ratio was significantly lower (P = .02) in HPV-16-positive patients. A higher percentage of CD8 cells was associated with response to induction chemotherapy (P = .02) and complete tumor response after chemoradiotherapy (P = .045). CONCLUSION: these findings confirm previous correlations of outcome with circulating CD8 cell levels and support the conjecture that improved adaptive immunity may play a role in the favorable prognosis of patients with HPV-16-positive cancers.
Authors: Jessica H Maxwell; Bhavna Kumar; Felix Y Feng; Francis P Worden; Julia S Lee; Avraham Eisbruch; Gregory T Wolf; Mark E Prince; Jeffrey S Moyer; Theodoros N Teknos; Douglas B Chepeha; Jonathan B McHugh; Susan G Urba; Jay Stoerker; Heather M Walline; David M Kurnit; Kitrina G Cordell; Samantha J Davis; Preston D Ward; Carol R Bradford; Thomas E Carey Journal: Clin Cancer Res Date: 2010-02-09 Impact factor: 12.531
Authors: Nicky Sirianni; Patrick K Ha; Mattias Oelke; Joseph Califano; William Gooding; William Westra; Theresa L Whiteside; Wayne M Koch; Jonathan P Schneck; Albert DeLeo; Robert L Ferris Journal: Clin Cancer Res Date: 2004-10-15 Impact factor: 12.531
Authors: Kent A Smith; Brenna L Meisenburg; Victor L Tam; Robb R Pagarigan; Raymond Wong; Diljeet K Joea; Liz Lantzy; Mayra A Carrillo; Todd M Gross; Uriel M Malyankar; Chih-Sheng Chiang; Diane M Da Silva; Thomas M Kündig; W Martin Kast; Zhiyong Qiu; Adrian Bot Journal: Clin Cancer Res Date: 2009-09-29 Impact factor: 12.531
Authors: Sonia A Duffy; David L Ronis; Scott McLean; Karen E Fowler; Stephen B Gruber; Gregory T Wolf; Jeffrey E Terrell Journal: J Clin Oncol Date: 2009-03-16 Impact factor: 44.544
Authors: Francis P Worden; Bhavna Kumar; Julia S Lee; Gregory T Wolf; Kitrina G Cordell; Jeremy M G Taylor; Susan G Urba; Avraham Eisbruch; Theodoros N Teknos; Douglas B Chepeha; Mark E Prince; Christina I Tsien; Nisha J D'Silva; Kun Yang; David M Kurnit; Heidi L Mason; Tamara H Miller; Nancy E Wallace; Carol R Bradford; Thomas E Carey Journal: J Clin Oncol Date: 2008-05-12 Impact factor: 44.544
Authors: G T Wolf; S Schmaltz; J Hudson; H Robson; T Stackhouse; K A Peterson; J A Poore; K D McClatchey Journal: Arch Otolaryngol Head Neck Surg Date: 1987-11
Authors: Nesrine I Affara; Brian Ruffell; Terry R Medler; Andrew J Gunderson; Magnus Johansson; Sophia Bornstein; Emily Bergsland; Martin Steinhoff; Yijin Li; Qian Gong; Yan Ma; Jane F Wiesen; Melissa H Wong; Molly Kulesz-Martin; Bryan Irving; Lisa M Coussens Journal: Cancer Cell Date: 2014-06-05 Impact factor: 31.743
Authors: Derrick Wansom; Emily Light; Dafydd Thomas; Francis Worden; Mark Prince; Susan Urba; Douglas Chepeha; Bhavna Kumar; Kitrina Cordell; Avraham Eisbruch; Jeremy Taylor; Jeffrey Moyer; Carol Bradford; Nisha D'Silva; Thomas Carey; Jonathan McHugh; Gregory Wolf Journal: Laryngoscope Date: 2012-01 Impact factor: 3.325
Authors: Anna E Arthur; Sonia A Duffy; Gloria I Sanchez; Stephen B Gruber; Jeffrey E Terrell; James R Hebert; Emily Light; Carol R Bradford; Nisha J D'Silva; Thomas E Carey; Gregory T Wolf; Karen E Peterson; Laura S Rozek Journal: Nutr Cancer Date: 2011-06-11 Impact factor: 2.900
Authors: Josiah Ochieng; Gladys N Nangami; Olugbemiga Ogunkua; Isabelle R Miousse; Igor Koturbash; Valerie Odero-Marah; Lisa J McCawley; Pratima Nangia-Makker; Nuzhat Ahmed; Yunus Luqmani; Zhenbang Chen; Silvana Papagerakis; Gregory T Wolf; Chenfang Dong; Binhua P Zhou; Dustin G Brown; Anna Maria Colacci; Roslida A Hamid; Chiara Mondello; Jayadev Raju; Elizabeth P Ryan; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Amedeo Amedei; Rabeah Al-Temaimi; Fahd Al-Mulla; William H Bisson; Sakina E Eltom Journal: Carcinogenesis Date: 2015-06 Impact factor: 4.944
Authors: Zipei Feng; Daniel Bethmann; Matthias Kappler; Carmen Ballesteros-Merino; Alexander Eckert; R Bryan Bell; Allen Cheng; Tuan Bui; Rom Leidner; Walter J Urba; Kent Johnson; Clifford Hoyt; Carlo B Bifulco; Juergen Bukur; Claudia Wickenhauser; Barbara Seliger; Bernard A Fox Journal: JCI Insight Date: 2017-07-20